FTC Order Slams POM Claims; Firm Vows Appeal
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission’s 5-0 decision against POM Wonderful backs the ALJ’s cease-and-desist order and requires the firm to conduct at least two randomized controlled clinical trials for all disease-related claims going forward. POM vows to appeal the order in federal court.